Lord, Abbett & Co
ADMA icon

Lord, Abbett & Co’s ADMA Biologics ADMA Stock Holding History

Lord, Abbett & Co’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,781,524
Closed -$32.4M – 530
2025
Q2 		$32.4M Sell
1,781,524
-460,099
-21% -$9.38M 0.1% 221
2025
Q1 		$44.5M Buy
2,241,623
+34,346
+2% +$594K 0.16% 162
2024
Q4 		$37.9M Sell
2,207,277
-887,180
-29% -$16.7M 0.12% 216
2024
Q3 		$61.9M Buy
+3,094,457
New +$48.1M 0.2% 146

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.82B AUM 73.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Lord, Abbett & Co's ADMA Position: Q3 2025 in Review

Lord, Abbett & Co sold out of ADMA Biologics (ADMA) in Q3 2025, closing a stake of 1,781,524 shares — an estimated $32.4M sold.

Lord, Abbett & Co first reported a position in ADMA in Q3 2024 and held it in 4 quarters. The position peaked at $61.9M in Q3 2024. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Lord, Abbett & Co reported no remaining ADMA Biologics position as of Q3 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 1,781,524 ADMA Biologics shares in Q3 2025, an estimated $32.4M.
  • Lord, Abbett & Co first reported a position in ADMA Biologics in Q3 2024 and held it in 4 quarters.
  • Lord, Abbett & Co's ADMA Biologics position peaked at $61.9M in Q3 2024.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Lord, Abbett & Co's 13F filing for Q3 2025, filed 13 Nov 2025.